Thermo Fisher Scientific (TMO)
NYSE: TMO · Diagnostics & Research · Waltham, MA
Our rating: Neutral
Neutral reaffirmed at $682.65, moderate conviction, November 2, 2026.
Breaks if: Would turn Positive if annual revenue growth reaches 7% or above in the next reported fiscal year, signaling that end-market recovery — biotech funding and pharma capital spending — has genuinely arrived and given the premium multiple something to lean on. Would turn Cautious if free cash flow falls below $5.5B or annual revenue growth decelerates below 2% in the next reported year; at that point 38.5x earnings would rest on reputation rather than trajectory, and the current price would be difficult to defend on any near-term earnings path.
Key figures
| Market value | $248.1B |
|---|---|
| Revenue, last 12 months | $47.4B |
| Net income, last 12 months | $7.1B |
| Free cash flow, last 12 months | $7.6B |
| Price to earnings | 35.1× |
| Free cash flow yield | 3.1% |
| Dividend yield | 0.3% |
| Operating margin | 17.9% |
| Return on equity | 13.4% |
| Beta to the S&P 500 | 0.74 |
| Volatility, annualized | 29.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 26, 2026 | $12.1B | 9.1% | $4.64 | $2.1B |
| June 27, 2026 | $12.0B | 10.5% | $4.68 | $1.7B |
| March 28, 2026 | $11.0B | 6.2% | $4.43 | $816M |
| December 31, 2025 | $12.2B | 7.2% | $5.21 | $3.0B |
| September 27, 2025 | $11.1B | 4.9% | $4.27 | $1.8B |
| June 28, 2025 | $10.9B | 3.0% | $4.28 | $1.1B |
| March 29, 2025 | $10.4B | 0.2% | $3.98 | $361M |
| December 31, 2024 | $11.4B | 4.7% | $4.78 | $2.8B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $13.2B: Claude 42%, Gemini 85%, Mistral 68%
- Diluted earnings per share are at least $5.21: Claude 55%, Gemini 80%, Mistral 32%
- Free cash flow for the quarter is at least $2.99B: Claude 45%, Gemini 90%, Mistral 52%
- Backlog at the end of the quarter is at least $29.9B: Claude 60%, Gemini 95%, Mistral 88%
15 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.